$42.3 M

BLPH Mkt cap, 29-Jul-2021
Bellerophon Therapeutics Net income (Q1, 2021)-5.5 M
Bellerophon Therapeutics EBIT (Q1, 2021)-5.9 M
Bellerophon Therapeutics Cash, 31-Mar-202139.7 M
Bellerophon Therapeutics EV4.1 M
Get notified regarding key financial metrics and revenue changes at Bellerophon TherapeuticsLearn more
Banner background

Bellerophon Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.3m14.5m28.8m16.6m9.9m47.6m

Prepaid Expenses

5.4m3.4m650.0k405.0k420.0k

Current Assets

29.5m26.5m35.6m17.4m10.4m48.1m

PP&E

1.8m1.4m1.0m664.0k316.0k169.0k

Total Assets

38.4m29.7m36.8m18.4m13.1m50.2m

Accounts Payable

1.6m2.8m3.9m2.8m3.1m3.7m

Short-term debt

658.0k704.0k

Current Liabilities

8.1m6.5m7.1m7.5m7.6m10.4m

Long-term debt

1.7m956.0k

Total Debt

2.3m1.7m

Total Liabilities

8.1m11.7m39.4m14.5m9.5m12.0m

Common Stock

131.0k569.0k587.0k46.0k95.0k

Preferred Stock

Additional Paid-in Capital

130.9m142.2m176.2m179.8m193.3m252.6m

Retained Earnings

(100.7m)(124.5m)(179.3m)(176.5m)(189.8m)(214.5m)

Total Equity

30.3m18.0m(2.6m)3.9m3.6m38.2m

Financial Leverage

1.3 x1.7 x-14.2 x4.8 x3.7 x1.3 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

62.9m48.5m23.9m1.3m1.3m3.9m13.5m11.0m32.3m28.4m23.4m19.6m20.7m16.8m12.8m8.6m59.3m54.0m39.7m

Prepaid Expenses

2.0m1.8m1.4m5.7m5.4m6.4m6.4m5.4m3.9m3.0m2.5m1.7m948.0k825.0k712.0k349.0k903.0k633.0k446.0k

Current Assets

73.6m60.9m46.9m23.1m18.6m17.5m23.2m20.4m39.4m34.8m28.8m22.5m21.7m17.7m13.7m9.0m60.3m54.7m40.2m

PP&E

1.6m1.5m1.8m1.7m1.6m1.5m1.3m1.2m1.1m935.0k845.0k755.0k576.0k488.0k401.0k270.0k228.0k198.0k140.0k

Total Assets

75.2m62.4m49.2m31.2m26.3m22.8m25.8m22.4m40.9m35.9m29.8m23.6m24.8m20.6m16.6m11.6m62.7m57.0m42.2m

Accounts Payable

659.0k966.0k934.0k641.0k2.0m2.2m3.9m2.8m2.8m4.6m4.1m4.4m2.6m2.8m2.3m2.2m2.8m3.8m3.8m

Short-term debt

669.0k680.0k692.0k716.0k

Current Liabilities

12.8m11.2m8.6m7.3m6.2m4.8m6.1m5.5m6.4m8.4m9.0m9.1m7.3m6.7m7.0m6.8m6.6m9.0m8.1m

Long-term debt

1.9m1.7m1.8m1.5m1.3m1.1m773.0k

Total Debt

1.9m1.7m1.8m2.2m2.0m1.8m1.5m

Total Liabilities

12.8m11.2m8.6m7.3m6.2m4.8m25.0m23.1m25.2m33.7m37.6m19.7m14.5m9.1m9.3m9.4m9.3m11.2m9.1m

Common Stock

129.0k129.0k130.0k135.0k139.0k145.0k330.0k352.0k550.0k574.0k578.0k587.0k689.0k689.0k689.0k49.0k95.0k95.0k95.0k

Preferred Stock

Additional Paid-in Capital

129.4m129.8m130.2m131.5m132.8m134.9m144.1m146.4m170.3m176.9m178.3m178.9m186.9m192.2m192.3m196.8m251.9m252.3m253.0m

Retained Earnings

(67.1m)(78.7m)(89.9m)(107.7m)(112.9m)(117.1m)(143.6m)(147.6m)(155.2m)(175.2m)(186.7m)(175.6m)(177.3m)(181.4m)(185.7m)(194.7m)(198.6m)(206.5m)(220.0m)

Total Equity

62.4m51.2m40.5m23.9m20.1m18.0m800.0k(787.0k)15.7m2.2m(7.8m)3.9m10.3m11.5m7.3m2.1m53.4m45.9m33.1m

Financial Leverage

1.2 x1.2 x1.2 x1.3 x1.3 x1.3 x32.2 x-28.4 x2.6 x16.2 x-3.8 x6 x2.4 x1.8 x2.3 x5.4 x1.2 x1.2 x1.3 x

Bellerophon Therapeutics Cash Flow

Bellerophon Therapeutics Ratios

USDQ1, 2015

Financial Leverage

1.2 x